Next Phase Newsletter

A global pharmaceutical company headquartered in Japan with US offices specializes in ophthalmology and rheumatology medicines. The firm considers licensing later stage (Phase III and on) assets to enrich their pipeline, and support early stage biotech companies by co-investing with other venture firms where there is already a lead in place. The firm will initially invest $1-2 M, and up to $5 M throughout the life of the investment.

The firm is interested in research stage innovation in platform technologies, gene/cell therapies, device and drug delivery systems, bio markers, etc. Current areas of interests are: Retinal Disorders (Uveitis, Age-related macular degeneration, Diabetic macular edema), Glaucoma (Intraocular pressure reduction, Neuroprotection), and Corneal Disorders (Dry eye, Corneal epithelial defects). The firm’s European interests also includes orphan indications and drug delivery technologies.

The firm requires a lead venture firm to be in place before considering co-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A newly established corporate venture fund established by an instrumentation company invests in a wide array of applications of genomics. The firm seeks to syndicate with other leading institutional and strategic investors in Series A rounds. Typical allocations range from $2-5 million initially and can be up to $15-20 million over the life span of the company. The firm expects to make 4-5 new investments over the next 12 months and considers opportunities globally with a focus on the Bay area.

The firm is interested in areas where its expertise and special relationship with its parent company can add value. The firm focuses on applications of genomics including sequencing, assay development, agriculture and environmental science, industrial biotech, digital health, public safety and personal wellness, proteomics and other ‘omics’ areas. The firm prefers pre-revenue companies that have achieved proof-of-concept.

The firm seeks to work with experienced management teams with sector expertise. The firm’s team members have decades of entrepreneurial experience in genomics and may request a board seat depending on the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

One of the largest medical equipment companies in China is seeking partnership opportunities worldwide. The firm specializes in R&D, manufacturing and distribution of medical equipment. The firm is looking globally for collaboration, in-licensing, and M&A opportunities in medtech innovations that has a China angle. The firm typically seeks distribution rights in the Chinese market.

Within medtech, the firm is looking for technologies that can complement its existing product lines in respiratory system, circulatory system, endocrine system, home care, and hospital equipment. The firm has a special interest in disposable medical materials, digital devices, respiratory care equipment, and sleep monitoring technologies. The firm prefers class I and 510k devices that are within 1-2 years to FDA clearance.

The firm is seeking innovative technologies that can address unmet medical need in the Chinese market. Yuwell can utilize its manufacturing facilities to reduce production cost and leverage a marketing network and distribution channels of more than 150 service centers all over China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm with investment teams in Silicon Valley and Switzerland is currently investing out of its second fund, and looks to invest in early-stage life science companies crossing all sectors. The firm focuses on Seed, Series A and Series B investments. Investment is in the form of equity with the firm making roughly 3-5 new investments per year. The firm typically invests $500K – $5M per round (depending on the stage and needs of the company), and generally invests $10-$15M throughout the life of a company. The firm is very comfortable leading investment rounds, and focuses on companies in the US and Europe.

In the life sciences, the firm is looking for new investment opportunities in the therapeutics, diagnostics, tools and medical device sectors. The firm is opportunistic in terms of sub-sectors and indications. The firm is only interested in preclinical/Phase I, early-stage technology. The firm looks for companies with proprietary technologies that allow them to address unmet needs in a unique and compelling manner. The firm is not interested in healthcare IT, healthcare services or software companies.

The firm invests in privately-held companies with passionate founders and/or a strong management team. The firm looks to take a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A foundation based in the US Midwest makes allocations to companies in the range of $1-$8 million and is capable of providing $10-$15m over the investments lifetime. The foundation’s goal is to support specific products or technologies to benefit patients. The foundation does not look to take an equity position in companies but they do look for an ROI to return capital to the foundation upon commercialization of the technology or change in ownership. The foundation primarily funds companies located in the United States but will consider opportunities located globally as well.

The foundation’s mission is to fund research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa (RP),  usher syndrome, and the entire spectrum of inherited retinal degenerative diseases. The foundation is currently looking to fund companies in the therapeutics sector and will consider companies working in areas of small molecules, biologics, gene therapy, and regenerative medicine that target those indications. The Foundation primarily funds companies that are just preparing to enter the IND enabling stage, companies in pre-clinical through Phase II clinical trials will also be considered.

The foundation has a world class Scientific Advisory Board, and in addition to financial support, it provides significant technical and clinical guidance to the projects/companies it funds. Since the foundation often supports companies that do not have complete management teams, the the foundation provides expertise and access to many experts in the field that will help aid companies. In addition the foundation has a registry of potential patients for clinical trials and close relationships with key players in the ophthalmic pharmaceutical industry to help facilitate collaborations.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment group founded by a wealthy family has operation in China and the US. The group is actively seeking new investments in the life sciences across the US, and it occasionally invests in companies in Europe. The group focuses on pre-clinical and clinical stage companies. The investment size will vary and typically it ranges from $2 million -$10 million. The group has no set number of allocations over the next 6-9 months.

In the life sciences, the firm is looking for new investments in the biotech therapeutics sector. The group will also consider investing in medical devices and diagnostics opportunities, however that is not their main focus area. The firm is open to both 510K and PMA medical devices. For therapeutics, the group is most interested in biologics. The group invests in a variety of therapeutic areas with a focus on oncology. The group generally invests in pre-clinical stage companies without clinical data, and it also syndicates with other investors for clinical-stage investments.

The firm invests in privately-held life science companies. The group is generally not interested in commercial-stage companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US-based venture firm that builds companies around early stage technologies is investing from a $400 million fund.  The firm is seeking to invest in therapeutic assets and is open to opportunites globally.

The firm is currently interested immunology assets that aim to treat infectious diseases (viral and bacterial), with a focus on assets related to immune priming or changing the immune system. Any therapeutic modality is of interest, including vaccines. The firm is interested in reviewing immunology assets at any stage of development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com